Cumulative incidence of VTE within 12 months of treatment initiation for newly diagnosed multiple myeloma with death as a competing risk. The 6- and 12-month cumulative incidence of VTE was 8.2% (95% CI, 6.6-10.1) and 11.5% (95% CI, 9.5-13.6), respectively.